Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

nesvacumab

A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinas e (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-ANG2 MoAb REGN910
anti-ANG2 monoclonal antibody REGN910
Code name:REGN910
SAR307746
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search